Quarterly report pursuant to Section 13 or 15(d)

INTANGIBLE ASSETS

v3.23.3
INTANGIBLE ASSETS
 9 Months Ended
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS

6. INTANGIBLE ASSETS

 

The net carrying value of the identifiable intangible assets from all acquisitions as of September 30, 2023 and December 31, 2022 are as follows:

 

         

As of

September 30, 2023

    

As of

December 31, 2022

  
    Life     Carrying     Carrying  
    (Years)     Amount     Amount  
                   
Asuragen acquisition:                      
Thyroid   9     $ 8,519     $ 8,519  
RedPath acquisition:                      
Pancreas test   7       16,141       16,141  
Barrett’s test   9       6,682       6,682  
                       
CLIA Lab   2.3       609       609  
                       
Total         $ 31,951     $ 31,951  
                       
Accumulated Amortization           (31,924 )     (31,090 )
                       
Net Carrying Value         $ 27     $ 861  

 

Amortization expense was approximately $0.2 million and $0.3 million for the three-month periods ended September 30, 2023 and 2022, respectively, and $0.8 million and $1.0 million for the nine-month periods ended September 30, 2023 and 2022, respectively. The remaining amortization expense of approximately $27,000 will be amortized in 2023.